1. Home
  2. VERO vs XRTX Comparison

VERO vs XRTX Comparison

Compare VERO & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Venus Concept Inc.

VERO

Venus Concept Inc.

HOLD

Current Price

$1.87

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$0.61

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERO
XRTX
Founded
N/A
2011
Country
Canada
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
4.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VERO
XRTX
Price
$1.87
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.1K
50.0K
Earning Date
11-13-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,876,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.65
$0.52
52 Week High
$14.50
$1.79

Technical Indicators

Market Signals
Indicator
VERO
XRTX
Relative Strength Index (RSI) 46.16 46.51
Support Level $1.84 $0.61
Resistance Level $1.99 $0.67
Average True Range (ATR) 0.12 0.03
MACD 0.01 0.01
Stochastic Oscillator 44.78 50.45

Price Performance

Historical Comparison
VERO
XRTX

About VERO Venus Concept Inc.

Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: